Table 3.
Clinical characteristics, distribution of pathogens, and percentage of antibiotic resistance of 33 children with ventilator-associated pneumonia and positive results with the FilmArray Pneumonia Panel plus.
| Patients with VAP | Total (n = 33) |
|---|---|
| Age (median, minimum–maximum) | 66 (2–210) |
| Gender (boy/girl) | |
| Comorbidities | 28 (84%) |
| Neurological disease | 14 (42%) |
| Cardiac disease | 5 (15%) |
| Metabolic disease | 4 (12%) |
| Hemato-oncological disease | 2 (6%) |
| Central catheter n (%) | 29 (88%) |
| Total parenteral nutrition n (%) | 16 (49%) |
| Enteral nutrition n (%) | 32 (97%) |
| Sedo-analgesia n (%) | 31 (94%) |
| Inotrope n (%) | 19 (58%) |
| Tracheostomy n (%) | 9 (27%) |
| ANTIBIOTIC TREATMENT | |
| Continuation (same as) | 13 (39.4%) |
| Escalation | 18 (54.5%) |
| De-escalation | 2 (6.1%) |
| POSITIVE FA-PP RESULTS | N = 44 |
| Single/multiple pathogens | 15/29 |
| Bacteria | |
| Pseudomonas aeruginosa | 17 (38.6%) |
| Klebsiella pneumoniae-oxytoca | 19 (43.1%) |
| Acinetobacter calcoaceticus-baumannii complex | 14 (31.8%) |
| Serratia marcescens | 7 (15.9%) |
| Haemophilus influenzae | 2 (4.5%) |
| Escherichia coli | 5 (11.3%) |
| Staphylococcus aureus | 4 (9.0%) |
| Streptococcus pneumoniae | 2 (4.5%) |
| Enterobacter cloacae complex | 3 (6.8%) |
| Proteus spp. | 1 (2.2%) |
| Antibiotic resistance | |
| CTX-M (Cefotaximase-Munich) | 11 (25.0%) |
| KPC (Klebsiella pneumoniae carbapenemase) | 17 (38.6%) |
| NDM (New Delhi metallo-beta-lactamase) | 3 (6.8%) |
| OXA-48 (OXA-48 carbapenemase) | 3 (6.8%) |
| VIM (Verona Integron-encoded Metallo-beta-lactamase) | 0 (%) |
| Mec-A/C (Methicillin resistance gene) | 3 (6.8%) |
| Viruses | 16 (25%) |
| One/multiple | 13/3 |
| Rhinovirus/enterovirus | 9 (20.4%) |
| RSV | 3 (6.8%) |
| Human metapneumovirus | 2 (4.5%) |
| Adenovirus | 4 (9.0%) |
| Influenza A/B | 3 (6.8%) |